

State of the TB Alliance: An Update

Mel Spigelman, M.D.
Chief Executive Officer &
President

TB Alliance Vision




6 - 30 months

Success will require novel multi-drug combinations

TB Alliance Update (PPP)

- People
- Portfolio
- Pesos


TB Alliance Organizational Chart




<u> TB Alliance Portfolio 2009</u> CLINICAL DEVELOPMENT **DISCOVERY** TB ALLIANCE Lead Lead **PROGRAMS Preclinical** Phase I Phase III Phase II Identification **Optimization** Moxifloxacin **Bayer PA-824 TB Alliance TMC-207** Tibotec/J&J == **Quinolone TBK-613** KRICT/Yonsei **Nitroimidazoles** ACSRC/UIC Mycobact. Gyrase Inhibitors **GSK** Riminophenazines **IMM/BTTTRI** InhA Inhibitors **GSK** Tibotec/J&J — **Diarylquinolines Dual-Action Molecules** ACSRC/CSU **Tryptanthrines** KRICT/Yonsei Phenotypic Screening HTL **UIC/BioDuro LeuRS Inhibitors** Anacor — **GSK Whole-Cell Screening GSK Malate Synthase Inhibitors GSK/TAMU** Menaguinone Syn Inhibitors CSU 🛑 **Natural Products** IMCAS/BTTTRI **RNAP Inhibitors** Rutgers **EM Inhibitors UPenn Protease Inhibitors IDRI Topoisomerase I Inhibitors** NYMC **NITD Portfolio**



Global Clinical Portfolio New TB Drugs in Registration Programs




TB Alliance Portfolio Positioning




- TB Alliance's relative involvement in the global TB drug pipeline increases from early to late stages
- Presence in discovery allows the TB Alliance to step in at any stage to help optimize and advance promising projects and to better pursue the clinical development programs

TB Alliance 2003-2009 Spending




2009 Projected Expenditures

~\$42mm



Portfolio Investment – External Expenses



- Clinical development costs drive expenses consequence of success
- Discovery investment has reached steady state; discovery portfolio increase is mainly supported by cost saving and leveraging external resources
- Discovery projects leverage approximately \$2 of external resources for every \$1 of TB Alliance investment

Opportunity

Challenge

Significantly improve TB therapy (drug sensitive and resistant TB)

Mobilize the necessary resources to execute against the present plan

Thank you!